ATOSSA THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
ATOSSA THERAPEUTICS, INC. (ATOS) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$1.28 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-28.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2019-03-28
- ATOSSA THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-12-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-09-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2017 was -$1.28M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $0.00 derived: sum of 2 quarters · filed 2019-03-28 | -$1.28M 10-K · filed 2019-03-28 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$1.28M 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | -$1.28M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |